SciSparc Ltd. (NASDAQ:SPRC) Short Interest Up 277.7% in July

SciSparc Ltd. (NASDAQ:SPRC) saw a large increase in short interest during the month of July. As of July 31st, there was short interest totaling 37,966 shares, an increase of 277.7% from the July 15th total of 10,052 shares. Based on an average daily trading volume, of 747,372 shares, the short-interest ratio is presently 0.1 days. Approximately 6.8% of the shares of the stock are short sold.

SciSparc Stock Down 1.5%

SPRC stock traded down $0.10 during mid-day trading on Friday, reaching $6.59. The company’s stock had a trading volume of 9,168 shares, compared to its average volume of 572,264. The company’s 50 day moving average is $6.51 and its two-hundred day moving average is $5.84. SciSparc has a fifty-two week low of $2.98 and a fifty-two week high of $80.10.

Analyst Upgrades and Downgrades

SPRC has been the subject of a number of research analyst reports. Wall Street Zen raised SciSparc to a “hold” rating in a report on Saturday, July 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SciSparc in a research note on Tuesday, May 26th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

SciSparc Company Profile

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.